advagraf prolonged release hard capsules 5 mg
astellas pharma singapore pte. ltd. - tacrolimus monohydrate 5.1 mg eqv anhydrous tacrolimus 5.0 mg - capsule, extended release - 5.0 mg - tacrolimus monohydrate 5.1 mg eqv anhydrous tacrolimus 5.0 mg 5.0 mg
vesicare tablet 10mg
astellas pharma singapore pte. ltd. - solifenacin succinate - tablet, film coated - 10mg/tablet - solifenacin succinate 10 mg
vesicare tablet 5mg
astellas pharma singapore pte. ltd. - solifenacin succinate - tablet, film coated - 5mg/tablet - solifenacin succinate 5 mg
veoza fezolinetant 45 mg film coated tablet blister pack
astellas pharma australia pty ltd - fezolinetant, quantity: 45 mg - tablet, film coated - excipient ingredients: mannitol; hyprolose; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 8000; purified talc; iron oxide red - veoza is indicated for the treatment of moderate to severe vasomotor symptoms (vms) associated with menopause (see section 5.1 pharmacodynamic properties ? clinical trials)
harnal ocas prolonged release film-coated tablet 400mcg
astellas pharma singapore pte. ltd. - tamsulosin hydrochloride - tablet, film coated, extended release - 0.4mg/tablet - tamsulosin hydrochloride 0.4 mg
betmiga ® prolonged-release tablets 25mg
astellas pharma singapore pte. ltd. - mirabegron - tablet, film coated, extended release - 25 mg - mirabegron 25 mg
betmiga ® prolonged-release tablets 50mg
astellas pharma singapore pte. ltd. - mirabegron - tablet, film coated, extended release - 50 mg - mirabegron 50 mg
betmiga 25 mg
astellas pharma international b.v., israel - mirabegron - tablets prolonged release - mirabegron 25 mg - mirabegron - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (oab) syndrome
betmiga 25 mg
astellas pharma international b.v., israel - mirabegron - tablets prolonged release - mirabegron 25 mg - mirabegron - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (oab) syndrome
betmiga 50 mg
astellas pharma international b.v., israel - mirabegron - tablets prolonged release - mirabegron 50 mg - mirabegron - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (oab) syndrome